Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could fewer HPV vaccine doses offer lasting protection?

NCT ID NCT07706673

Prevention Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Sep 02, 2026 · Updated 13 times

Summary

This study follows women who previously received either one or two doses of the Gardasil9 HPV vaccine to see how long protection against HPV infection lasts. Researchers will check for persistent infections with HPV types linked to cancer. The goal is to understand if fewer doses still provide strong, long-term immunity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HPV vaccine (Gardasil9)
What this could lead to
If successful, this could show that one or two doses of the HPV vaccine provide long-lasting protection, potentially simplifying vaccination schedules and increasing global access.
What could go wrong
This is an observational follow-up, not a new treatment test. Protection may wane over time, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 13,700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * TRIAL PARTICIPANTS: Participation in ESCUDDO base study * TRIAL PARTICIPANTS: Randomization (excluding the two participants who had major protocol deviations in the ESCUDDO base study) to the Gardasil9 1- and 2-dose arms * TRIAL PARTICIPANTS: A signed informed consent form for ESCUDDO LTFU * TRIAL PARTICIPANTS: Opportunity to complete three total study visits * LTFU SURVEY GROUP: We will match the current ages of ESCUDDO LTFU trial participants when they attend their 9.5-year study visit (21 to 26 years of age) Exclusion Criteria: * TRIAL PARTICIPANTS: Enrollment cannot occur beyond her 10 year study visit * LTFU SURVEY GROUP: They report they are pregnant * LTFU SURVEY GROUP: They report being vaccinated against HPV * LTFU SURVEY GROUP: The qualified healthcare personnel determining eligibility, in agreement with principal investigator, considers a reason that precludes participation; or * LTFU SURVEY GROUP: They do not have an identification document

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papillomavirus infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papillomavirus-related squamous cell carcinoma human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human papillomavirus infection Human papillomavirus-related malignant neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Agencia Costarricense de Investigaciones Biomédicas (ACIB)

    Liberia, Guanacaste Province, 50101, Costa Rica

More trials for these conditions

Other studies related to the condition(s) this trial covers.